Chapter 16 of 25
What you will learn
- Understand when carboplatin and paclitaxel are used.
- Prepare for cycles, monitoring and supportive medicines.
- Recognize symptoms that require immediate contact.
Why chemotherapy is considered
The team may recommend chemotherapy for high-risk postoperative disease or advanced and recurrent cancer. The decision uses stage, histology, molecular findings, previous treatment and fitness. It is not determined solely by whether the uterus has been removed. In selected advanced settings, chemotherapy is combined with immunotherapy and followed by maintenance immunotherapy.
Carboplatin and paclitaxel are commonly used together. Carboplatin damages cancer-cell DNA; paclitaxel interferes with cell division. Both also affect some healthy cells, explaining many adverse effects. A treatment cycle includes the administration day and a recovery period. The number and timing of cycles depend on the regimen, purpose and tolerance; this guide does not provide prescribing instructions.
Before and during treatment
Blood counts, kidney and liver function are checked, along with symptoms and physical fitness. Carboplatin dosing depends partly on kidney function, so accurate assessment matters. Existing neuropathy, diabetes, hearing problems, allergies and previous chemotherapy reactions should be discussed. Paclitaxel usually requires medicines to reduce infusion-reaction risk.
Antinausea medicines are prescribed preventively and for breakthrough symptoms. Some patients need growth-factor support to reduce infection risk, depending on regimen and individual factors. A delay or dose adjustment may be necessary for safety and does not automatically mean treatment has failed. Tell the team about herbs, supplements and nonprescription medicines because interactions are possible.
Common adverse effects
| Effect | What to discuss |
|---|---|
| Low white cells | Fever plan and emergency contact |
| Anaemia or low platelets | Breathlessness, fatigue, bruising or bleeding |
| Tingling or numbness | Early reporting before neuropathy becomes disabling |
| Nausea, appetite change or constipation | Preventive medicines and symptom-specific support |
| Hair loss and fatigue | Practical preparation, rest and activity balance |
| Infusion reaction | Immediate reporting during treatment |
Neuropathy can affect balance, buttons, writing or walking and may persist. Describe functional changes rather than waiting until symptoms are severe. Hair usually regrows after treatment, but texture and timing vary. Fatigue can have several causes, including anaemia, poor sleep, mood symptoms and disease itself; it deserves assessment rather than a simple instruction to push through.
When urgent help is needed
Follow the treating centre's temperature threshold. A temperature of 38°C or higher during chemotherapy generally warrants immediate contact, and feeling severely unwell can be urgent even without fever. Shaking chills, confusion, breathlessness, uncontrolled vomiting, inability to drink or significant bleeding require prompt assessment. Do not wait for the next cycle or take fever-reducing medicine as a substitute for calling.
During an infusion, tell staff immediately about itching, flushing, chest tightness, back pain or breathing difficulty. At home, sudden chest pain, collapse or severe breathlessness requires emergency care. Keep the regimen name and emergency telephone number accessible to family members.
Questions and take-home messages
Ask what benefit is expected, whether immunotherapy is part of the plan, how response will be assessed and what findings would change treatment. If chemotherapy is not recommended, ask which low-risk features support observation. More treatment is not always safer or more effective; the aim is an appropriate balance of benefit and burden.
Related chapters
- Immunotherapy in Endometrial Cancer
- Molecular Classification: The Four Major Groups
- How Doctors Choose Treatment
References and review status
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- NCI: Endometrial Cancer Treatment, patient version
- FDA pembrolizumab–chemotherapy approval / KEYNOTE-868, June 2024
- FDA expanded dostarlimab–chemotherapy indication, August 2024
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy